By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic testing firm Signal Genetics has agreed to buy molecular diagnostics company ChipDx for an undisclosed amount.

Under the terms of the deal announced today, Signal will acquire all of ChipDx's assets, including its patents for its prognostic tests for lung, breast, and colon cancers. It is buying BreastGeneDX, ColonGeneDX, and LungGeneDX, as well as all diagnostic and prognostic tests under development by ChipDx.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.